Showing posts with label study. Show all posts
Showing posts with label study. Show all posts

Tuesday, September 17, 2013

0 Putting health status guided COPD management to the test: protocol of the MARCH study

Open Access


Study protocol


Putting health status guided COPD management to the test: protocol of the MARCH study



Janwillem Kocks, Corina de Jong, Marjolein Y Berger, Huib AM Kerstjens and Thys van der Molen










For all author emails, please log on.








BMC Pulmonary Medicine 2013, 13:41 doi:10.1186/1471-2466-13-41

Published: 4 July 2013





Abstract (provisional)


Background


Chronic Obstructive Pulmonary Disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible and usually progressive. Current guidelines, among which the Dutch, have so far based their management strategy mainly on lung function impairment as measured by FEV1, while it is well known that FEV1 has a poor correlation with almost all features of COPD that matter to patients. Based on this discrepancy the GOLD 2011 update included symptoms and impact in their treatment algorithm proposal. Health status measures capture both symptoms and impact and could therefore be used as a standardized way to capture the information a doctor could otherwise only collect by careful history taking and recording. We hypothesize that a treatment algorithm that is based on a simple validated 10 item health status questionnaire, the Clinical COPD Questionnaire (CCQ), improves health status (as measured by SGRQ) and classical COPD outcomes like exacerbation frequency, patient satisfaction and health care utilization compared to usual care based on guidelines.

Methods


This hypothesis will be tested in a randomized controlled trial (RCT) following 330 patients for two years. During this period general practitioners will receive treatment advices every four months that are based on the patient’s health status (in half of the patients, intervention group) or on lung function (the remaining half of the patients, usual care group).

Discussion


During the design process, the selection of outcomes and the development of the treatment algorithm were challenging. This is discussed in detail in the manuscript to facilitate researchers in designing future studies in this changing field of implementation research.

Trial registration Number: NTR2643






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.



0 Best strategies to implement clinical pathways in an emergency department setting. Study protocol in asthma and gastroenteriris.

Open Access


Study protocol


Best strategies to implement clinical pathways in an emergency department setting: study protocol for a cluster randomized controlled trial



Mona Jabbour, Janet Curran, Shannon D Scott, Astrid Guttman, Thomas Rotter, Francine M Ducharme, M Diane Lougheed, M Louise McNaughton-Filion, Amanda Newton, Mark Shafir, Alison Paprica, Terry Klassen, Monica Taljaard,Jeremy Grimshaw and David W Johnson










For all author emails, please log on.








Implementation Science 2013, 8:55 doi:10.1186/1748-5908-8-55

Published: 22 May 2013





Abstract (provisional)


Background


The clinical pathway is a tool that operationalizes best evidence recommendations and clinical practice guidelines in an accessible format for `point of care? management by multidisciplinary health teams in hospital settings. While high-quality, expert-developed clinical pathways have many potential benefits, their impact has been limited by variable implementation strategies and suboptimal research designs. Best strategies for implementing pathways into hospital settings remain unknown. This study will seek to develop and comprehensively evaluate best strategies for effective local implementation of externally developed expert clinical pathways. Design/methods We will develop a theory-based and knowledge user-informed intervention strategy to implement two pediatric clinical pathways: asthma and gastroenteritis. Using a balanced incomplete block design, we will randomize 16 community emergency departments to receive the intervention for one clinical pathway and serve as control for the alternate clinical pathway, thus conducting two cluster randomized controlled trials to evaluate this implementation intervention. A minimization procedure will be used to randomize sites. Intervention sites will receive a tailored strategy to support full clinical pathway implementation. We will evaluate implementation strategy effectiveness through measurement of relevant process and clinical outcomes. The primary process outcome will be the presence of an appropriately completed clinical pathway on the chart for relevant patients. Primary clinical outcomes for each clinical pathway include the following: Asthma?the proportion of asthmatic patients treated appropriately with corticosteroids in the emergency department and at discharge; and Gastroenteritis?the proportion of relevant patients appropriately treated with oral rehydration therapy. Data sources include chart audits, administrative databases, environmental scans, and qualitative interviews. We will also conduct an overall process evaluation to assess the implementation strategy and an economic analysis to evaluate implementation costs and benefits.

Discussion


This study will contribute to the body of evidence supporting effective strategies for clinical pathway implementation, and ultimately reducing the research to practice gaps by operationalizing best evidence care recommendations through effective use of clinical pathways. Trial registration ClinicalTrials.gov: NCT01815710






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.



Monday, September 16, 2013

Case Study Challenge: Check Your CC Knowledge by Studying These Detailed Scenarios

You want clinical critical care examples? You got them here.


The details of critical care coding are difficult to determine without some concrete examples to illustrate 99291 scenarios. So what does a really detailed clinical scenario for critical care look like?


Here are the two medical billing and coding scenarios to throw more light.


The challenge: Look at these case studies and see in case you can get all the codes — diagnosis (ICD-9) and procedure/service (CPT) — right:


Scenario 1: Physician Treats CHF


A patient comes to the ED with deteriorating shortness of breath (SOB); the physician observes the patient and discovers high blood pressure and tachycardia. The physician orders a Cardizem drip to control the patient’s heart rate; she after that orders labs, a chest x-ray, and an electrocardiogram (EKG).


The physician carries out multiple re-evaluations, interprets both the x-ray and EKG, and diagnoses congestive heart failure as well as atrial fibrillation. Total encounter time is 50 minutes; the EKG interpretation takes the physician four minutes.


Answer: On the claim, you must report the following:



  • CPT code 99291 (Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes) for the 46 minutes of critical care;

  • modifier 25 (Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service) appended to 99291 to display that the critical care and EKG were distinct services, in case your payer requires it;

  • CPT code 93010 (Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only) for the EKG;

  • ICD-9 code 428.0 (Congestive heart failure, unspecified) appended to 99291 and 93010 to signify the patient’s heart failure;

  • ICD-9 code 427.31 (Atrial fibrillation) appended to 99291 and 93010 to signify the patient’s atrial fibrillation; and

  • ICD-9 code 786.05 (Shortness of breath) appended to 99291 and 93010 to signify the patient’s symptoms.


Scenario 2: Physician Treats Respiratory Failure


A patient comes to the ED with dyspnea and wheezing; the history portion of the exam discloses the patient has asthma. The physician finds the patient in respiratory distress with retractions as well as accessory muscle use. He then orders labs, a chest x-ray, an EKG, and an ABG (arterial blood gas).


The patient gets three rounds of Albuterol and Atrovent Nebs, and steroids by mouth. The physician carries out multiple re-evaluations, interprets the x-rays, EKG, and ABG. The patient starts having evidently increased difficulty breathing in one of the re-evals, and the physician places the patient on BiPAP (bilevel positive airway pressure). In spite of the BiPAP, the patient’s rapid deterioration stays.


The ED physician intubates the patient and then admits him to the intensive care unit (ICU). Final diagnosis is asthma and also acute respiratory failure. The physician documents 110 minutes of encounter time with the patient; the physician spent five minutes on intubation and five minutes interpreting the EKG.


Answer: On this claim, you must report the following ICD-9 codes and CPT codes :



  • 99291 (for the first 74 minutes of critical care);

  • +99292 (… each additional 30 minutes [List separately in addition to code for primary procedure]) for the remaining 26 minutes of critical care;

  • modifier 25 (appended to 99291 and +99292 to show that the critical care and the other procedures were separate services, if the payer requires it);

  • 31500 (Intubation, endotrachael, emergency procedure) for the intubation;

  • 93010 for the EKG interpretation;

  • 518.81 (Acute respiratory failure; appended to 99291, +99292, 31500, and 93010 to represent the patient’s respiratory failure)

  • 493.90 (Asthma, unspecified; appended to 99291, +99292, 31500, and 93010 to represent the patient’s asthma diagnosis)


Sunday, September 15, 2013

0 A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations



Logo of rhinol

American Journal of Rhinology & Allergy










Am J Rhinol Allergy. 2013 Mar-Apr; 27(2): 98–101.

Published online 2013 January 30. doi:  10.2500/ajra.2013.27.3850




PMCID: PMC3610944





A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations: Data from a pilot study



Matthew A. Rank, M.D.,corresponding author1 John B. Hagan, M.D.,2 Shefali A. Samant, M.D.,2 and Hirohito Kita, M.D.2







Abstract




Background:


One way to gain insight into the pathophysiology of chronic rhinosinusitis (CRS) is to study the immunologic changes that occur with exacerbation. This study describes the immunologic changes during CRS exacerbation



Methods:


We performed a prospective study to investigate the immunologic changes seen during exacerbation of CRS with nasal polyposis. We recruited adult subjects who met clinical criteria for CRS with sinus CT scan within the past 5 years with Lund-Mackay score of >5 and nasal polyps. Subjects underwent a baseline visit with collection of nasal secretion and nasal wash. With acute worsening of symptoms, subjects underwent 6 near-consecutive-day collections and one follow-up collection 2 weeks later. IL-6, IL-33, eosinophil major basic protein (MBP), eosinophil-derived neurotoxin (EDN), myeloperoxidase (MPO), and uric acid were measured on the nasal samples from each visit.



Results:


A total of 10 subjects were recruited and 9 had acute worsening of CRS during the study period. Eight of the nine subjects were women and ages ranged from 26 to 56 years. At baseline, most inflammatory parameters were low and eight of the nine subjects were on intranasal corticosteroids. Compared with baseline measurements, IL-6, MBP, MPO, EDN, and uric acid were significantly elevated during CRS exacerbation. Levels of IL-6 and MBP (r = 0.47) levels as well as IL-6 and MPO (r = 0.75) were both significantly correlated (p < 0.01).



Conclusion:


Prospective study of CRS exacerbations is feasible and provides insights into the immunologic mechanisms of CRS.


Formats:








Saturday, September 14, 2013

0 Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study

Thorax 68:658-663 doi:10.1136/thoraxjnl-2012-203109Epidemiology


  • Original article



Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study


Open Access









  1. Jeffrey A Johnson1


+Author Affiliations




  1. 1Department of Public Health Sciences, University of Alberta, Edmonton, Canada




  2. 2Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada




  3. 3Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada





  1. Correspondence toDr Jeffrey A Johnson, 2-040G Li Ka Shing Center for Health Research Innovation, 8602 112 Street, Department of Public Health Sciences, University of Alberta, Edmonton, Canada, AB T6G 2E1; jeff.johnson@ualberta.ca



  • Received 7 December 2012

  • Revised 7 February 2013

  • Accepted 2 March 2013

  • Published Online First 27 March 2013




Abstract



Background Guidelines recommend influenza vaccinations in all diabetic adults, but there is limited evidence to support vaccinating working-age adults (65>



Methods We identified all adults with diabetes, along with a sample of age-matched and sex-matched comparison subjects without diabetes, from 2000 to 2008, using administrative data from Manitoba, Canada. With multivariable Poisson regression, we estimated vaccine effectiveness (VE) on influenza-like illnesses (ILIs), pneumonia and influenza (PI) hospitalisations and all-cause (ALL) hospitalisations during periods of known circulating influenza. Analyses were replicated outside of influenza season to rule out residual confounding.



Results We included 543 367 person-years of follow-up, during which 223 920 ILI, 5422 PI and 94 988 ALL occurred. The majority (58%) of adults with diabetes were working age. In this group, influenza vaccination was associated with relative reductions in PI (43%, 95% CI 28% to 54%) and ALL (28%, 95% CI 24% to 32%) but not ILI (−1%, 95% CI −3% to 1%). VE was similar in elderly adults for ALL (33–34%) and PI (45–55%), although not ILI (12–13%). However, similar estimates of effectiveness were also observed for all three groups during non-influenza control periods.



Conclusions Working-age adults with diabetes experience similar benefits from vaccination as elderly adults, supporting current diabetes-specific recommendations. However, these benefits were also manifest outside of influenza season, suggesting residual bias. Vaccination recommendations in all high-risk adults would benefit from randomised trial evidence.

This Article







  1. Supplementary Data


  2. All Versions of this Article:

    1. thoraxjnl-2012-203109v1

    2. 68/7/658 most recent









This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ andhttp://creativecommons.org/licenses/by-nc/3.0/legalcode